Cartesian Therapeutics Inc
NASDAQ:RNAC
Cartesian Therapeutics Inc
NASDAQ:RNAC
Price:
6.5
USD
0.15%
Market Closed
Market Cap:
$169m
Balance Sheet
Balance Sheet Decomposition
Cartesian Therapeutics Inc
Cartesian Therapeutics Inc
Balance Sheet Decomposition is not available for
Cartesian Therapeutics Inc
Cartesian Therapeutics Inc
Balance Sheet
Cartesian Therapeutics Inc
Cartesian Therapeutics Inc
Currency: USD
| Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & Cash Equivalents |
17
|
32
|
59
|
71
|
37
|
90
|
139
|
114
|
106
|
77
|
213
|
|
| Cash Equivalents |
17
|
32
|
59
|
71
|
37
|
90
|
139
|
114
|
106
|
77
|
213
|
|
| Short-Term Investments |
0
|
4
|
25
|
26
|
0
|
0
|
0
|
14
|
28
|
0
|
0
|
|
| Total Receivables |
1
|
1
|
0
|
0
|
0
|
5
|
7
|
10
|
10
|
9
|
1
|
|
| Accounts Receivables |
1
|
1
|
0
|
0
|
0
|
5
|
7
|
10
|
7
|
6
|
1
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
3
|
3
|
0
|
|
| Other Current Assets |
2
|
2
|
2
|
2
|
5
|
2
|
5
|
6
|
4
|
5
|
3
|
|
| Total Current Assets |
19
|
39
|
87
|
99
|
42
|
97
|
151
|
144
|
148
|
91
|
217
|
|
| PP&E Net |
2
|
2
|
2
|
2
|
2
|
2
|
12
|
12
|
14
|
12
|
15
|
|
| PP&E Gross |
2
|
2
|
2
|
2
|
2
|
2
|
12
|
12
|
14
|
12
|
15
|
|
| Accumulated Depreciation |
3
|
3
|
4
|
4
|
5
|
5
|
4
|
5
|
5
|
6
|
2
|
|
| Intangible Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
151
|
151
|
|
| Goodwill |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
48
|
48
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
2
|
2
|
2
|
|
| Other Long-Term Assets |
1
|
2
|
0
|
0
|
0
|
1
|
2
|
1
|
1
|
1
|
2
|
|
| Other Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
48
|
48
|
|
| Total Assets |
22
N/A
|
43
+93%
|
89
+109%
|
101
+13%
|
44
-56%
|
100
+124%
|
165
+66%
|
160
-3%
|
166
+4%
|
305
+84%
|
435
+43%
|
|
| Liabilities | ||||||||||||
| Accounts Payable |
0
|
2
|
4
|
2
|
1
|
1
|
0
|
0
|
0
|
3
|
0
|
|
| Accrued Liabilities |
2
|
3
|
4
|
9
|
12
|
14
|
9
|
12
|
16
|
18
|
15
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
3
|
0
|
4
|
0
|
21
|
19
|
0
|
6
|
8
|
0
|
0
|
|
| Other Current Liabilities |
5
|
2
|
2
|
1
|
1
|
2
|
72
|
54
|
1
|
47
|
8
|
|
| Total Current Liabilities |
9
|
7
|
14
|
11
|
35
|
35
|
82
|
72
|
25
|
68
|
23
|
|
| Long-Term Debt |
5
|
12
|
8
|
21
|
0
|
0
|
25
|
20
|
18
|
0
|
0
|
|
| Deferred Income Tax |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
16
|
16
|
|
| Other Liabilities |
2
|
3
|
13
|
17
|
15
|
56
|
77
|
45
|
29
|
361
|
403
|
|
| Total Liabilities |
16
N/A
|
22
+37%
|
34
+57%
|
49
+44%
|
50
+1%
|
91
+83%
|
183
+101%
|
137
-25%
|
72
-48%
|
445
+517%
|
442
-1%
|
|
| Equity | ||||||||||||
| Common Stock |
94
|
137
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
301
|
0
|
|
| Retained Earnings |
84
|
112
|
152
|
217
|
280
|
336
|
405
|
430
|
395
|
615
|
692
|
|
| Additional Paid In Capital |
0
|
0
|
211
|
273
|
280
|
349
|
391
|
457
|
493
|
179
|
690
|
|
| Unrealized Security Profit/Loss |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Equity |
4
|
5
|
5
|
4
|
5
|
5
|
5
|
5
|
5
|
5
|
5
|
|
| Total Equity |
6
N/A
|
21
+234%
|
55
+162%
|
52
-6%
|
5
N/A
|
8
N/A
|
18
N/A
|
23
N/A
|
94
+317%
|
140
N/A
|
7
+95%
|
|
| Total Liabilities & Equity |
22
N/A
|
43
+93%
|
89
+109%
|
101
+13%
|
44
-56%
|
100
+124%
|
165
+66%
|
160
-3%
|
166
+4%
|
305
+84%
|
435
+43%
|
|
| Shares Outstanding | ||||||||||||
| Common Shares Outstanding |
0
|
0
|
1
|
1
|
1
|
3
|
4
|
4
|
5
|
5
|
26
|
|
| Preferred Shares Outstanding |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Switch to:
Switch to:
See Also
Discover More
